About Senopsys

Frequently Asked Questions About Pharmaceutical Taste Assessment and Taste Masking

Human taste assessment should begin immediately after successful Phase I clinical studies, when clinical viability is established and formulation decisions become critical.

Early quantitative taste data:

  • Supports pediatric regulatory planning
  • Reduces formulation trial-and-error
  • Improves dosage form selection
  • Lowers risk of failed acceptability studies
  • Helps avoid late-stage reformulation

Early palatability decisions shorten timelines and reduce overall program risk.

Senopsys uses GCP-compliant trained human sensory analysis panels to quantify aversive taste, aroma, mouthfeel, and texture attributes of APIs and drug product formulations.

Because human sensory perception remains the clinically relevant model for oral acceptability, this approach provides development data that instrumental methods alone cannot fully replicate.

Study outputs are used to guide formulation design, prototype comparison, and development strategy.

Yes. Senopsys studies are designed using controlled sensory methods and documented under quality systems appropriate for inclusion in regulatory submissions, including:

  • INDs
  • NDAs
  • MAAs
  • Pediatric Investigation Plans (EMA)
  • Pediatric Study Plans (FDA)

Reports support formulation rationale, palatability strategy, and excipient justification.

Human sensory systems remain the only clinically relevant model for human oral perception.

Trained pharmaceutical sensory panels can:

  • Identify all aversive attributes (taste, aroma, and mouthfeel)
  • Measure attribute onset and intensity
  • Generate temporal profiles of impact and duration (aftertaste)
  • Determine taste recognition threshold concentrations
  • Assess flavor quality of prototype formulations

For many APIs, these combined effects define the true taste masking challenge.

This provides formulation teams with development data directly relevant to patient acceptability.

Senopsys supports taste assessment and taste masking across a wide range of dosage forms, including:

  • Liquids - solutions and suspensions
  • Powders and sachets
  • Mini-tablets, granules, and multiparticulates
  • Chewable and orally disintegrating tablets (ODTs)
  • Films
  • Oral sprays

We also routinely work with potent, poorly soluble, and otherwise challenging APIs.

Many APIs have multiple aversive sensory attributes simultaneously, including bitterness, burning, numbing, unpleasant odor, and a long aftertaste. Identifying which attributes dominate is often the key to successful formulation strategy.

Senopsys may not be the best fit when:

  • Palatability is unlikely to affect dosage form acceptance
  • A program remains at preclinical stage
  • Instrumental screening alone is the primary objective
  • Manufacturing is the principal need
  • The formulation falls outside GCP-based pharmaceutical development (e.g., dietary supplements or recreational cannabis products)

When appropriate, we recommend alternative resources.

Explore selected publications, presentations, and case studies related to pharmaceutical palatability and taste masking.

Many formulation teams also benefit from a Lunch & Learn seminar—a scientific overview of taste perception, sensory data interpretation, taste masking strategy, and formulation decision-making in pharmaceutical development.

Contact Senopsys to schedule a scientific discussion.

Dedicated to Developing Palatable Drug Products

Senopsys is the taste-masking development partner of choice for 15 of the top 25 global pharma companies as well as dozens of emerging and mid-size pharma and biotech companies.

Ask us questions, inquire about our services or schedule a “lunch and learn” seminar about the art and science of taste masking.

CONTACT US